JAZZ
Jazz Pharmaceuticals PLC
NASDAQ: JAZZ · HEALTHCARE · BIOTECHNOLOGY
$199.92
-1.99% today
Updated 2026-04-29
Market cap
$12.54B
P/E ratio
—
P/S ratio
2.94x
EPS (TTM)
$-5.83
Dividend yield
—
52W range
$98 – $207
Volume
1.0M
Jazz Pharmaceuticals PLC (JAZZ) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-8.35%
Operating margin
27.10%
ROE
-8.47%
ROA
5.38%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $44.86M | $-59.39M | 84.47% | -174.01% | -132.40% |
| 2007 | $65.30M | $-138.83M | 86.37% | -212.51% | -212.59% |
| 2008 | $67.51M | $-184.34M | 79.38% | -252.34% | -273.04% |
| 2009 | $128.45M | $-6.84M | 92.50% | 12.40% | -5.32% |
| 2010 | $173.78M | $32.78M | 92.20% | 33.25% | 18.86% |
| 2011 | $272.28M | $124.98M | 94.88% | 46.95% | 45.90% |
| 2012 | $585.98M | $288.59M | 86.62% | 33.76% | 49.25% |
| 2013 | $872.42M | $216.31M | 88.29% | 39.01% | 24.79% |
| 2014 | $1.17B | $58.39M | 89.99% | 16.68% | 4.98% |
| 2015 | $1.32B | $329.54M | 92.26% | 38.36% | 24.87% |
| 2016 | $1.49B | $396.83M | 92.92% | 39.76% | 26.67% |
| 2017 | $1.62B | $487.85M | 93.19% | 32.67% | 30.14% |
| 2018 | $1.89B | $447.10M | 93.57% | 32.52% | 23.64% |
| 2019 | $2.16B | $523.37M | 94.08% | 24.63% | 24.21% |
| 2020 | $2.36B | $238.62M | 93.70% | 16.00% | 10.10% |
| 2021 | $3.09B | $-328.95M | 85.76% | 5.50% | -10.63% |
| 2022 | $3.66B | $-224.06M | 85.23% | -1.79% | -6.12% |
| 2023 | $3.83B | $414.83M | 88.64% | 15.09% | 10.82% |
| 2024 | $4.07B | $560.12M | 89.05% | 17.61% | 13.77% |
| 2025 | $4.27B | $-356.15M | 88.21% | 5.26% | -8.35% |